Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. - Wikidata - awgldk - TriplyDB

Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression.

Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression.

http://www.wikidata.org/entity/Q36067596

about

The lipid phosphatase activity of PTEN is critical for its tumor supressor function STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors Interaction of the tumor suppressor PTEN/MMAC with a PDZ domain of MAGI3, a novel membrane-associated guanylate kinase Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2 PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells mediated by p27kip1 NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN X-linked inhibitor of apoptosis protein (XIAP) regulates PTEN ubiquitination, content, and compartmentalization PTEN inhibits BMI1 function independently of its phosphatase activity PTEN function: how normal cells control it and tumour cells lose it Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility Deletion, mutation, and loss of expression of KLF6 in human prostate cancer Pten dose dictates cancer progression in the prostate Advances in genetics: widening our understanding of prostate cancer Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer The androgen receptor and stem cell pathways in prostate and bladder cancers (review)Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.Therapeutic targeting of cancers with loss of PTEN function.FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer Mechanisms regulating tumor angiogenesis by 12-lipoxygenase in prostate cancer cells Male breast cancer in Cowden syndrome patients with germline PTEN mutations Loss of PTEN permits CXCR4-mediated tumorigenesis through ERK1/2 in prostate cancer cells Modulators of prostate cancer cell proliferation and viability identified by short-hairpin RNA library screening Combined PDGFR and HDAC Inhibition Overcomes PTEN Disruption in Chordoma Shank-interacting protein-like 1 promotes tumorigenesis via PTEN inhibition in human tumor cells.Cyclin-dependent kinase 5 acts as a critical determinant of AKT-dependent proliferation and regulates differential gene expression by the androgen receptor in prostate cancer cells Adenoviral-mediated pHyde gene transfer and cisplatin additively inhibit human prostate cancer growth by enhancing apoptosis.A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer.The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway.MYC oncogenes and human neoplastic disease.Endogenous antibodies for tumor detection SGK3 is an androgen-inducible kinase promoting prostate cancer cell proliferation through activation of p70 S6 kinase and up-regulation of cyclin D1.Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer.PTEN gene and integrin signaling in cancer.Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity.Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines.Hypoxia-induced down-regulation of neprilysin by histone modification in mouse primary cortical and hippocampal neurons.PTEN 2, a Golgi-associated testis-specific homologue of the PTEN tumor suppressor lipid phosphatase.Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo.

P2860

Q22007981-B6091C86-0680-41FA-8D84-A026DFFC698D Q22010908-88B89269-0E6A-4E51-A5AF-31DB6C5F440E Q22253438-36441491-87D2-4508-ADD7-0B3E3C46F2EF Q22253866-D0347817-EBEC-4DFD-870C-713D0E1CBAF0 Q22254699-860A5A62-491B-4ED1-99E2-AE98EEBF07BF Q24292919-FE4B8287-C5C8-4030-8516-4C962C53DAFE Q24314543-D6B81DAE-4A57-44B4-A85C-A322F61E908C Q24315949-CE029D23-5164-4ED4-996A-E827146731EA Q24528114-C8F5FB1F-EAEE-48E6-8EB4-00B0A0507615 Q24679438-3594C9D2-DDBD-4869-88CD-8CAF82F49B31 Q24684163-E1B8B001-E05C-46EB-A7D0-9BEB8F221700 Q24791909-80847BF2-16B3-4F26-B17E-B90CF0E08DE9 Q26740628-8C213881-9093-4395-901A-0D51A9EF9567 Q26752510-7D2D9438-84AB-45E6-8689-220DFBD6F24D Q26773634-CF6780C9-08D7-4024-B8B3-2F194894E0DE Q26853232-924E3816-C322-4C74-BBEB-6ABA444D4907 Q27824772-CCDA48DA-8ADE-498B-AD38-EF57176050CA Q27851411-DB7A20E3-DCB5-4A7D-853B-9EEF3832A1B7 Q27852764-3D520084-0F12-48F5-BB44-7B8BCC0E0C2E Q28204251-D4EDFB50-9C35-4757-87A7-56449874B115 Q28236579-CB666EB4-3062-4CB3-BA51-122D088881B0 Q28359884-0A39D610-5207-4FF9-83E8-D53A44D1EA51 Q28388722-545A0BA8-3203-4158-B3DC-174DBDC017B0 Q28482249-2BE6FA62-ACBF-41D1-A17C-91C560B684D5 Q30278895-0BC14EDE-4159-47E9-AC7E-272CA44037C5 Q30494717-112C2923-087F-4CEB-8686-0D13B4714A1F Q30654792-100DBEAC-A49A-458D-82C3-36E56FCE4031 Q33385228-D1F16B37-5AE4-4B53-929C-91E13F5F6A1B Q33389796-A716A5C7-AC80-4E8E-A871-43C0DC63399B Q33599964-B602071D-BE70-42F6-A555-08AE2F768DD5 Q33667340-9C9A8D5C-9C0D-4DEF-890F-4682C745F8C0 Q33687275-9C450776-2D6D-42F5-9794-C198B122C7D6 Q33701389-A446A075-110B-4FF4-9439-07F5DB85A25B Q33723651-94A2BE1C-FA80-4938-98A4-3BD835264537 Q33765703-79F85195-1EBC-4063-BB76-F061E199C3F4 Q33774967-28A3EE57-3ACD-46D7-8080-90AEF1879219 Q33869038-64C8B9EA-F997-48CF-A5E6-2FCAA8C65040 Q33895062-E4DDC40C-46A9-4989-9C7F-76526A77AB8C Q33940647-9AC183D6-7D71-473D-A281-8ACDA68A538C Q33942901-FE066F0C-FD73-4F4C-848D-41DA914A517A

P2860

Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression.

http://www.wikidata.org/entity/Q36067596

description

1998 nî lūn-bûn

@nan

1998年の論文

@ja

1998年論文

@yue

1998年論文

@zh-hant

1998年論文

@zh-hk

1998年論文

@zh-mo

1998年論文

@zh-tw

1998年论文

@wuu

1998年论文

@zh

1998年论文

@zh-cn

name

Inactivation of the tumor supp ...... er through loss of expression.

@ast

Inactivation of the tumor supp ...... er through loss of expression.

@en

type

label

Inactivation of the tumor supp ...... er through loss of expression.

@ast

Inactivation of the tumor supp ...... er through loss of expression.

@en

prefLabel

Inactivation of the tumor supp ...... er through loss of expression.

@ast

Inactivation of the tumor supp ...... er through loss of expression.

@en

P1433

Q36067596-E55D1E48-1FAD-4DEA-88CF-DADDC137E665

P1476

Q36067596-94B537EA-F312-440F-8AA9-ABE1AA04A6A7

P2093

Q36067596-2778ADD3-57E3-4F03-B3A5-388AF853E2DE

Q36067596-27F2F7D8-C0A8-4056-A8B6-75A10E0F7FA0

Q36067596-5F182985-9234-40E4-B482-6B4C607FC226

Q36067596-7599AF42-5957-4358-A8CA-BAEB0621D6E3

Q36067596-7B004556-A6BE-46F0-A1A3-4807CACD7BD0

Q36067596-7F91F4F5-9879-40CF-BC7D-C66021F97678

Q36067596-C12DFBB4-310F-4F65-B8A1-960D11A8A31F

Q36067596-C6EA42B9-8263-48EF-8A82-66D6FF8E05A5

Q36067596-E286181D-8496-4038-B09A-CB723D195A6E

P2860

Q36067596-084B6A1F-BC07-410E-9DD7-2E335C49F6F8

Q36067596-08AFAB8D-7709-4C6F-825C-1FF85CBD6FA0

Q36067596-0CE85CDE-C087-49C7-A7CC-35B8A23DB726

Q36067596-1A711A2F-2D6A-4FDF-95D2-7745FA074B77

Q36067596-2093E132-9DEB-49DE-9086-0E0020B5D6FD

Q36067596-22273A0E-F8C0-4421-98D1-1E40D8595938

Q36067596-3974D5EB-95F5-47A2-90FD-D399E73BC842

Q36067596-420CEE64-012C-4A3D-A849-05214808C7AE

Q36067596-5379E576-CC6C-4A4F-B0B1-D333EB9572FD

Q36067596-5801D2B9-92F0-49D2-8AA6-BF5806069CFE

P304

Q36067596-45B90887-D746-4287-A158-596566404873

P31

Q36067596-3FAFAD6C-8AE8-49F6-BB57-2F12EA23B530

P356

Q36067596-0253D48F-EFAC-4D31-8F22-F42036E371E7

P407

Q36067596-F1F3F46C-4582-4818-9590-FC8033EC642B

P433

Q36067596-B91BE663-6C43-4129-A4BE-F88340A28401

P478

Q36067596-BC7F8E63-9BB5-4EC7-A830-36B763F3D60E

P577

Q36067596-3FC08E42-A0B6-43D4-B3B9-FB089F4DD58B

P5875

Q36067596-66F0B8F2-F6EB-43EE-BFB3-9DA3B3AD9635

P698

Q36067596-0C3D2EEE-C7AF-43D7-852B-4A22037354E9

P932

Q36067596-3F650669-290A-4D8C-AF54-A10F3D67A5B3

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Inactivation of the tumor supp ...... er through loss of expression.

@en

P2093

C L Sawyers

http://www.w3.org/2001/XMLSchema#string

C Tran

http://www.w3.org/2001/XMLSchema#string

H Suzuki

http://www.w3.org/2001/XMLSchema#string

J W Said

http://www.w3.org/2001/XMLSchema#string

R E Reiter

http://www.w3.org/2001/XMLSchema#string

R L Vessella

http://www.w3.org/2001/XMLSchema#string

W B Isaacs

http://www.w3.org/2001/XMLSchema#string

X Wu

http://www.w3.org/2001/XMLSchema#string

Y E Whang

http://www.w3.org/2001/XMLSchema#string

P2860

TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta

P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer

PTEN1 is frequently mutated in primary endometrial carcinomas

Simultaneous amplification of four DNA repair genes and beta-actin in human lymphocytes by multiplex reverse transcriptase-PCR

Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers

Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome

Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27

Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas.

Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice.

P304

5246-5250

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.95.9.5246

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

95

http://www.w3.org/2001/XMLSchema#string

P577

1998-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

13720696

http://www.w3.org/2001/XMLSchema#string

P698

9560261

http://www.w3.org/2001/XMLSchema#string

P932

20246

http://www.w3.org/2001/XMLSchema#string